Patents by Inventor Carlos Forray
Carlos Forray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7132248Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: October 31, 2002Date of Patent: November 7, 2006Assignee: H. Lundbeck A/SInventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
-
Patent number: 7060449Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: November 18, 2002Date of Patent: June 13, 2006Assignee: H. Lundbeck A/SInventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Patent number: 6790656Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: June 4, 1998Date of Patent: September 14, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Publication number: 20030215823Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: October 31, 2002Publication date: November 20, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
-
Publication number: 20030129702Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: November 18, 2002Publication date: July 10, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Christophe P.G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Patent number: 6586191Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: July 23, 1997Date of Patent: July 1, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
-
Publication number: 20030082672Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: July 23, 1997Publication date: May 1, 2003Inventors: KELLI E. SMITH, DAVID LINEMEYER, CHRISTOPHE GERALD, THERESA BRANCHEK, RICHARD L. WEINSHANK, CARLOS FORRAY
-
Publication number: 20030077701Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.Type: ApplicationFiled: December 20, 2001Publication date: April 24, 2003Inventors: Carlos Forray, John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson
-
Patent number: 6083705Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors.Type: GrantFiled: December 7, 1998Date of Patent: July 4, 2000Assignee: Synaptic Pharmaceuticals CorporationInventors: Jonathon A. Bard, Richard L. Weinshank, Carlos Forray
-
Patent number: 5972624Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the galanin receptor.Type: GrantFiled: April 1, 1996Date of Patent: October 26, 1999Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Patent number: 5861309Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.Type: GrantFiled: August 21, 1995Date of Patent: January 19, 1999Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Richard L. Weinshank, Carlos Forray
-
Patent number: 5714381Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor.Type: GrantFiled: June 6, 1995Date of Patent: February 3, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Carlos Forray, Richard L. Weinshank
-
Patent number: 5556753Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor and an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, an isolated protein which is a human .alpha..sub.1a adrenergic receptor, an isolated protein which is .alpha..sub.1b adrenergic receptor and a isolated protein which is a human .alpha..sub.1c adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor, and vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, mammalian cells comprising such vectors, antibodies directed to the human .alpha..sub.1a adrenergic receptor, antibodies directed to the human .alpha..sub.Type: GrantFiled: November 4, 1994Date of Patent: September 17, 1996Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Carlos Forray, Richard L. Weinshank